Literature DB >> 1436303

Intraglomerular foam cells and human focal glomerulosclerosis.

K W Schönholzer1, M Waldron, A B Magil.   

Abstract

Experimental evidence suggests a pathogenetic role for lipids in focal glomerulosclerosis (FGS) analogous to atherosclerosis. As foam cells (FC) are an important factor in atherosclerosis, a retrospective comparative study was done to evaluate the significance of intraglomerular FC in human FGS. Glomerular FC infiltration was evaluated in 115 biopsies of FGS, 120 biopsies of membranous glomerulonephritis (MGN) and 50 biopsies of minimal-change disease (MCD). Selected clinical and laboratory data collected at about the time of biopsy were reviewed. The proportion of biopsies showing glomerular FC was much higher in FGS (70%) than in either MGN (12%) or MCD (0%) p less than 0.001. The mean percent (+/- SD) of glomeruli with FC per biopsy was significantly greater in FGS (7.9 +/- 9.9) than in MGN (2.0 +/- 7.8; p less than 0.0001). Of the 14 MGN biopsies with FC, 13 showed superimposed FGS. Mean serum total cholesterol and triglyceride were not significantly higher in FGS than in either MGN or MCD. The results demonstrate a close association of glomerular FC infiltration with FGS.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1436303     DOI: 10.1159/000187020

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  3 in total

Review 1.  Lipid biology of the podocyte--new perspectives offer new opportunities.

Authors:  Alessia Fornoni; Sandra Merscher; Jeffrey B Kopp
Journal:  Nat Rev Nephrol       Date:  2014-05-27       Impact factor: 28.314

Review 2.  Arterial hypertension and hyperlipidemia as determinants of glomerulosclerosis.

Authors:  H J Gröne; A K Walli; E F Gröne
Journal:  Clin Investig       Date:  1993-10

3.  Hypertensive renal disease: susceptibility and resistance in inbred hypertensive rat lines.

Authors:  Michael C Braun; Stacy M Herring; Nisha Gokul; Monique Monita; Rebecca Bell; M John Hicks; Scott E Wenderfer; Peter A Doris
Journal:  J Hypertens       Date:  2013-10       Impact factor: 4.844

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.